Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina
November 30, 2021
The partnership will focus on the licensing, supply, and expected commercialization of Avicanna’s cannabinoid-based drug candidate Trunerox™, in Argentina in the second half 2022 TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the... Read more
